{"title": "Estimating the Case Fatality Risk of COVID-19 using Cases from Outside China", "doi": "10.1101/2020.02.15.20023499", "citation_id": "2020.02.15.20023499v1", "date": "2020-02-18", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.02.15.20023499", "abstract": "<p>There is large uncertainty around the case fatality risk (CFR) for COVID-19 in China. Therefore, we considered symptomatic cases outside of China (countries/settings with 20+ cases) and the proportion who are in intensive care units (4.0%, 14/349 on 13 February 2020). Given what is known about CFRs for ICU patients with severe respiratory conditions from a meta-analysis, we estimated a CFR of 1.37% (95%CI: 0.57% to 3.22%) for COVID-19 cases outside of China.</p>", "twitter_description": "There is large uncertainty around the case fatality risk (CFR) for COVID-19 in China. Therefore, we considered symptomatic cases outside of China (countries/settings with 20+ cases) and the proportion who are in intensive care units (4.0%, 14/349 on 13 February 2020). Given what is known about CFRs for ICU patients with severe respiratory conditions from a meta-analysis, we estimated a CFR of 1.37% (95%CI: 0.57% to 3.22%) for COVID-19 cases outside of China.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nNo external funding.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll data are displayed in the article as it is.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.15.20023499v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.02.15.20023499v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.15.20023499v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/18/2020.02.15.20023499.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.02.15.20023499v1", "access_rights": "restricted", "authors": ["Nick Wilson", "Amanda Kvalsvig", "Lucy Telfar Barnard", "Michael Baker"]}